NCT06753071View on ClinicalTrials.gov

The Efficacy of Pyridostigmine Therapy After Transurethral Resection of Prostate in Cases with Underactive Urinary Bladder.

PHASE4CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

April 1, 2024

Primary Completion Date

July 1, 2024

Study Completion Date

January 1, 2025

Conditions

Underactive BladderTURP(transurethral Resection of Prostate)BPH (Benign Prostatic Hyperplasia)

Interventions

DRUG

Pyridostigmine oral tablet

Pyridostigmine oral tablet, 60 mg, twice daily, for 3 months

DRUG

Placebo

Placebo oral tablet, twice daily, for 3 months

Trial Locations (1)

32511

Menoufia Faculty of Medicine, Shebin El-Kom

All Listed Sponsors

lead

Menoufia University

OTHER

NCT06753071 - The Efficacy of Pyridostigmine Therapy After Transurethral Resection of Prostate in Cases with Underactive Urinary Bladder. | Biotech Hunter | Biotech Hunter